Report Detail
Global (United States, European Union and China) Metastatic Melanoma Drug Market Research Report 2019-2025
- RnM3364233 |
- 01 July, 2020 |
- Global |
- 112 Pages |
- QYResearch |
- Pharma & Healthcare
Metastatic Melanoma Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Metastatic Melanoma Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Metastatic Melanoma Drug market is segmented into
AGI-134
ALT-801
ALT-803
AMG-232
Others
Segment by Application, the Metastatic Melanoma Drug market is segmented into
Hospital
Clinic
Others
Regional and Country-level Analysis
The Metastatic Melanoma Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Metastatic Melanoma Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Metastatic Melanoma Drug Market Share Analysis
Metastatic Melanoma Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Metastatic Melanoma Drug business, the date to enter into the Metastatic Melanoma Drug market, Metastatic Melanoma Drug product introduction, recent developments, etc.
The major vendors covered:
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Morphotek, Inc.
NewLink Genetics Corporation
Novartis AG
Omeros Corporation
Oncolytics Biotech Inc.
OncoSec Medical Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmis Biofarmaceutica, Lda.
Philogen S.p.A.
Plexxikon Inc.
1 Study Coverage
- 1.1 Metastatic Melanoma Drug Product Introduction
- 1.2 Market Segments
- 1.3 Key Metastatic Melanoma Drug Manufacturers Covered: Ranking by Revenue
- 1.4 Market by Type
- 1.4.1 Global Metastatic Melanoma Drug Market Size Growth Rate by Type
- 1.4.2 AGI-134
- 1.4.3 ALT-801
- 1.4.4 ALT-803
- 1.4.5 AMG-232
- 1.4.6 Others
- 1.5 Market by Application
- 1.5.1 Global Metastatic Melanoma Drug Market Size Growth Rate by Application
- 1.5.2 Hospital
- 1.5.3 Clinic
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Metastatic Melanoma Drug Market Size, Estimates and Forecasts
- 2.1.1 Global Metastatic Melanoma Drug Revenue 2015-2026
- 2.1.2 Global Metastatic Melanoma Drug Sales 2015-2026
- 2.2 Global Metastatic Melanoma Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
- 2.2.1 Global Metastatic Melanoma Drug Retrospective Market Scenario in Sales by Region: 2015-2020
- 2.2.2 Global Metastatic Melanoma Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Metastatic Melanoma Drug Competitor Landscape by Players
- 3.1 Metastatic Melanoma Drug Sales by Manufacturers
- 3.1.1 Metastatic Melanoma Drug Sales by Manufacturers (2015-2020)
- 3.1.2 Metastatic Melanoma Drug Sales Market Share by Manufacturers (2015-2020)
- 3.2 Metastatic Melanoma Drug Revenue by Manufacturers
- 3.2.1 Metastatic Melanoma Drug Revenue by Manufacturers (2015-2020)
- 3.2.2 Metastatic Melanoma Drug Revenue Share by Manufacturers (2015-2020)
- 3.2.3 Global Metastatic Melanoma Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
- 3.2.4 Global Top 10 and Top 5 Companies by Metastatic Melanoma Drug Revenue in 2019
- 3.2.5 Global Metastatic Melanoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Metastatic Melanoma Drug Price by Manufacturers
- 3.4 Metastatic Melanoma Drug Manufacturing Base Distribution, Product Types
- 3.4.1 Metastatic Melanoma Drug Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Metastatic Melanoma Drug Product Type
- 3.4.3 Date of International Manufacturers Enter into Metastatic Melanoma Drug Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
- 4.1 Global Metastatic Melanoma Drug Market Size by Type (2015-2020)
- 4.1.1 Global Metastatic Melanoma Drug Sales by Type (2015-2020)
- 4.1.2 Global Metastatic Melanoma Drug Revenue by Type (2015-2020)
- 4.1.3 Metastatic Melanoma Drug Average Selling Price (ASP) by Type (2015-2026)
- 4.2 Global Metastatic Melanoma Drug Market Size Forecast by Type (2021-2026)
- 4.2.1 Global Metastatic Melanoma Drug Sales Forecast by Type (2021-2026)
- 4.2.2 Global Metastatic Melanoma Drug Revenue Forecast by Type (2021-2026)
- 4.2.3 Metastatic Melanoma Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
- 4.3 Global Metastatic Melanoma Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
- 5.1 Global Metastatic Melanoma Drug Market Size by Application (2015-2020)
- 5.1.1 Global Metastatic Melanoma Drug Sales by Application (2015-2020)
- 5.1.2 Global Metastatic Melanoma Drug Revenue by Application (2015-2020)
- 5.1.3 Metastatic Melanoma Drug Price by Application (2015-2020)
- 5.2 Metastatic Melanoma Drug Market Size Forecast by Application (2021-2026)
- 5.2.1 Global Metastatic Melanoma Drug Sales Forecast by Application (2021-2026)
- 5.2.2 Global Metastatic Melanoma Drug Revenue Forecast by Application (2021-2026)
- 5.2.3 Global Metastatic Melanoma Drug Price Forecast by Application (2021-2026)
6 North America
- 6.1 North America Metastatic Melanoma Drug by Country
- 6.1.1 North America Metastatic Melanoma Drug Sales by Country
- 6.1.2 North America Metastatic Melanoma Drug Revenue by Country
- 6.1.3 U.S.
- 6.1.4 Canada
- 6.2 North America Metastatic Melanoma Drug Market Facts & Figures by Type
- 6.3 North America Metastatic Melanoma Drug Market Facts & Figures by Application
7 Europe
- 7.1 Europe Metastatic Melanoma Drug by Country
- 7.1.1 Europe Metastatic Melanoma Drug Sales by Country
- 7.1.2 Europe Metastatic Melanoma Drug Revenue by Country
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 U.K.
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Metastatic Melanoma Drug Market Facts & Figures by Type
- 7.3 Europe Metastatic Melanoma Drug Market Facts & Figures by Application
8 Asia Pacific
- 8.1 Asia Pacific Metastatic Melanoma Drug by Region
- 8.1.1 Asia Pacific Metastatic Melanoma Drug Sales by Region
- 8.1.2 Asia Pacific Metastatic Melanoma Drug Revenue by Region
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 South Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Taiwan
- 8.1.9 Indonesia
- 8.1.10 Thailand
- 8.1.11 Malaysia
- 8.1.12 Philippines
- 8.1.13 Vietnam
- 8.2 Asia Pacific Metastatic Melanoma Drug Market Facts & Figures by Type
- 8.3 Asia Pacific Metastatic Melanoma Drug Market Facts & Figures by Application
9 Latin America
- 9.1 Latin America Metastatic Melanoma Drug by Country
- 9.1.1 Latin America Metastatic Melanoma Drug Sales by Country
- 9.1.2 Latin America Metastatic Melanoma Drug Revenue by Country
- 9.1.3 Mexico
- 9.1.4 Brazil
- 9.1.5 Argentina
- 9.2 Central & South America Metastatic Melanoma Drug Market Facts & Figures by Type
- 9.3 Central & South America Metastatic Melanoma Drug Market Facts & Figures by Application
10 Middle East and Africa
- 10.1 Middle East and Africa Metastatic Melanoma Drug by Country
- 10.1.1 Middle East and Africa Metastatic Melanoma Drug Sales by Country
- 10.1.2 Middle East and Africa Metastatic Melanoma Drug Revenue by Country
- 10.1.3 Turkey
- 10.1.4 Saudi Arabia
- 10.1.5 U.A.E
- 10.2 Middle East and Africa Metastatic Melanoma Drug Market Facts & Figures by Type
- 10.3 Middle East and Africa Metastatic Melanoma Drug Market Facts & Figures by Application
11 Company Profiles
- 11.1 Merck & Co., Inc.
- 11.1.1 Merck & Co., Inc. Corporation Information
- 11.1.2 Merck & Co., Inc. Description and Business Overview
- 11.1.3 Merck & Co., Inc. Sales, Revenue and Gross Margin (2015-2020)
- 11.1.4 Merck & Co., Inc. Metastatic Melanoma Drug Products Offered
- 11.1.5 Merck & Co., Inc. Related Developments
- 11.2 Merck KGaA
- 11.2.1 Merck KGaA Corporation Information
- 11.2.2 Merck KGaA Description and Business Overview
- 11.2.3 Merck KGaA Sales, Revenue and Gross Margin (2015-2020)
- 11.2.4 Merck KGaA Metastatic Melanoma Drug Products Offered
- 11.2.5 Merck KGaA Related Developments
- 11.3 Millennium Pharmaceuticals, Inc.
- 11.3.1 Millennium Pharmaceuticals, Inc. Corporation Information
- 11.3.2 Millennium Pharmaceuticals, Inc. Description and Business Overview
- 11.3.3 Millennium Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
- 11.3.4 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Products Offered
- 11.3.5 Millennium Pharmaceuticals, Inc. Related Developments
- 11.4 Morphotek, Inc.
- 11.4.1 Morphotek, Inc. Corporation Information
- 11.4.2 Morphotek, Inc. Description and Business Overview
- 11.4.3 Morphotek, Inc. Sales, Revenue and Gross Margin (2015-2020)
- 11.4.4 Morphotek, Inc. Metastatic Melanoma Drug Products Offered
- 11.4.5 Morphotek, Inc. Related Developments
- 11.5 NewLink Genetics Corporation
- 11.5.1 NewLink Genetics Corporation Corporation Information
- 11.5.2 NewLink Genetics Corporation Description and Business Overview
- 11.5.3 NewLink Genetics Corporation Sales, Revenue and Gross Margin (2015-2020)
- 11.5.4 NewLink Genetics Corporation Metastatic Melanoma Drug Products Offered
- 11.5.5 NewLink Genetics Corporation Related Developments
- 11.6 Novartis AG
- 11.6.1 Novartis AG Corporation Information
- 11.6.2 Novartis AG Description and Business Overview
- 11.6.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
- 11.6.4 Novartis AG Metastatic Melanoma Drug Products Offered
- 11.6.5 Novartis AG Related Developments
- 11.7 Omeros Corporation
- 11.7.1 Omeros Corporation Corporation Information
- 11.7.2 Omeros Corporation Description and Business Overview
- 11.7.3 Omeros Corporation Sales, Revenue and Gross Margin (2015-2020)
- 11.7.4 Omeros Corporation Metastatic Melanoma Drug Products Offered
- 11.7.5 Omeros Corporation Related Developments
- 11.8 Oncolytics Biotech Inc.
- 11.8.1 Oncolytics Biotech Inc. Corporation Information
- 11.8.2 Oncolytics Biotech Inc. Description and Business Overview
- 11.8.3 Oncolytics Biotech Inc. Sales, Revenue and Gross Margin (2015-2020)
- 11.8.4 Oncolytics Biotech Inc. Metastatic Melanoma Drug Products Offered
- 11.8.5 Oncolytics Biotech Inc. Related Developments
- 11.9 OncoSec Medical Inc.
- 11.9.1 OncoSec Medical Inc. Corporation Information
- 11.9.2 OncoSec Medical Inc. Description and Business Overview
- 11.9.3 OncoSec Medical Inc. Sales, Revenue and Gross Margin (2015-2020)
- 11.9.4 OncoSec Medical Inc. Metastatic Melanoma Drug Products Offered
- 11.9.5 OncoSec Medical Inc. Related Developments
- 11.10 Ono Pharmaceutical Co., Ltd.
- 11.10.1 Ono Pharmaceutical Co., Ltd. Corporation Information
- 11.10.2 Ono Pharmaceutical Co., Ltd. Description and Business Overview
- 11.10.3 Ono Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
- 11.10.4 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Products Offered
- 11.10.5 Ono Pharmaceutical Co., Ltd. Related Developments
- 11.1 Merck & Co., Inc.
- 11.1.1 Merck & Co., Inc. Corporation Information
- 11.1.2 Merck & Co., Inc. Description and Business Overview
- 11.1.3 Merck & Co., Inc. Sales, Revenue and Gross Margin (2015-2020)
- 11.1.4 Merck & Co., Inc. Metastatic Melanoma Drug Products Offered
- 11.1.5 Merck & Co., Inc. Related Developments
- 11.12 Pharmis Biofarmaceutica, Lda.
- 11.12.1 Pharmis Biofarmaceutica, Lda. Corporation Information
- 11.12.2 Pharmis Biofarmaceutica, Lda. Description and Business Overview
- 11.12.3 Pharmis Biofarmaceutica, Lda. Sales, Revenue and Gross Margin (2015-2020)
- 11.12.4 Pharmis Biofarmaceutica, Lda. Products Offered
- 11.12.5 Pharmis Biofarmaceutica, Lda. Related Developments
- 11.13 Philogen S.p.A.
- 11.13.1 Philogen S.p.A. Corporation Information
- 11.13.2 Philogen S.p.A. Description and Business Overview
- 11.13.3 Philogen S.p.A. Sales, Revenue and Gross Margin (2015-2020)
- 11.13.4 Philogen S.p.A. Products Offered
- 11.13.5 Philogen S.p.A. Related Developments
- 11.14 Plexxikon Inc.
- 11.14.1 Plexxikon Inc. Corporation Information
- 11.14.2 Plexxikon Inc. Description and Business Overview
- 11.14.3 Plexxikon Inc. Sales, Revenue and Gross Margin (2015-2020)
- 11.14.4 Plexxikon Inc. Products Offered
- 11.14.5 Plexxikon Inc. Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
- 12.1 Metastatic Melanoma Drug Market Estimates and Projections by Region
- 12.1.1 Global Metastatic Melanoma Drug Sales Forecast by Regions 2021-2026
- 12.1.2 Global Metastatic Melanoma Drug Revenue Forecast by Regions 2021-2026
- 12.2 North America Metastatic Melanoma Drug Market Size Forecast (2021-2026)
- 12.2.1 North America: Metastatic Melanoma Drug Sales Forecast (2021-2026)
- 12.2.2 North America: Metastatic Melanoma Drug Revenue Forecast (2021-2026)
- 12.2.3 North America: Metastatic Melanoma Drug Market Size Forecast by Country (2021-2026)
- 12.3 Europe Metastatic Melanoma Drug Market Size Forecast (2021-2026)
- 12.3.1 Europe: Metastatic Melanoma Drug Sales Forecast (2021-2026)
- 12.3.2 Europe: Metastatic Melanoma Drug Revenue Forecast (2021-2026)
- 12.3.3 Europe: Metastatic Melanoma Drug Market Size Forecast by Country (2021-2026)
- 12.4 Asia Pacific Metastatic Melanoma Drug Market Size Forecast (2021-2026)
- 12.4.1 Asia Pacific: Metastatic Melanoma Drug Sales Forecast (2021-2026)
- 12.4.2 Asia Pacific: Metastatic Melanoma Drug Revenue Forecast (2021-2026)
- 12.4.3 Asia Pacific: Metastatic Melanoma Drug Market Size Forecast by Region (2021-2026)
- 12.5 Latin America Metastatic Melanoma Drug Market Size Forecast (2021-2026)
- 12.5.1 Latin America: Metastatic Melanoma Drug Sales Forecast (2021-2026)
- 12.5.2 Latin America: Metastatic Melanoma Drug Revenue Forecast (2021-2026)
- 12.5.3 Latin America: Metastatic Melanoma Drug Market Size Forecast by Country (2021-2026)
- 12.6 Middle East and Africa Metastatic Melanoma Drug Market Size Forecast (2021-2026)
- 12.6.1 Middle East and Africa: Metastatic Melanoma Drug Sales Forecast (2021-2026)
- 12.6.2 Middle East and Africa: Metastatic Melanoma Drug Revenue Forecast (2021-2026)
- 12.6.3 Middle East and Africa: Metastatic Melanoma Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Porter's Five Forces Analysis
- 13.5 Primary Interviews with Key Metastatic Melanoma Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Metastatic Melanoma Drug Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Metastatic Melanoma Drug. Industry analysis & Market Report on Metastatic Melanoma Drug is a syndicated market report, published as Global (United States, European Union and China) Metastatic Melanoma Drug Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Metastatic Melanoma Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
